The promise allogeneic NK cell and iPSC therapies hold

Cell and gene therapy developers are pursuing allogeneic approaches, which ideally could be produced in greater quantities and be available “off-the-shelf.” Those using natural killer (NK) cells and cells derived from induced pluripotent stem cells (iPSCs) are creating buzz in the industry. Drs. Sarah Cooley, Stephen Gottschalk and Stephan Grupp offer their insights.

Abby McDonald, PhD, is the manager of Solutions Development at Be The Match BioTherapies

Driving CAR-T therapy safety and sustainability for the road ahead

Autologous and allogeneic CAR-T therapies continue to hold significant promise for patients. But with that potential comes challenges, as more CAR-T therapies enter clinical trials and commercialization. Some are universal to both autologous CAR-T and allogeneic CAR-T, but each has its unique obstacles, too. Abby McDonald, PhD, supervises the Solutions Development team for Be The…